Stifel Maintains Buy on Nurix Therapeutics, Lowers Price Target to $35

Benzinga · 04/09 13:35
Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $36 to $35.